The independent financial analyst theScreener just lowered the general evaluation of ZHANGZHOU PIENTZEHUANG PHARMS.'A' (CN), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered moderately risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date January 7, 2022, the closing ...
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
Stay Defensive With Technology, Health Care, Staples Upside momentum continues to wane for global equities, a trend we mentioned in last week's Int'l Compass. In that report we highlighted early signs of lower highs forming in the major global indexes. Price action this week has indeed confirmed lower highs for now in the MSCI ACWI, ACWI ex-US, EAFE, and EM indexes. These lower highs increase the probability for breakdowns and a deeper pullback, but we do not want to get ahead of ourselves. Unt...
emain Overweight EM vs. EAFE The MSCI EM index (local currency) has continued to outperform relative to the MSCI EAFE index while the US dollar (DXY) forms a tight consolidation pattern. As a result we continue to favor EM over EAFE; and if EM is going to continue to outperform we would expect to see a breakdown below 98.50 support on the DXY. Like many global indexes, the MSCI EM index remains below resistance from a price perspective. Short-term levels we are watching include resistance at...
Lower High Forming? Major global indexes are showing waning upside momentum and we believe near-term consolidation is likely. This is supported by the charts and the idea that consolidation makes sense following the massive gains off of the March lows. We also believe that the market is in a “wait-and-see†phase as it relates to states and countries re-opening. A resolution of this consolidation period above resistance (bullish) or below support (bearish) will tell us where the major global...
Summary Zhangzhou Pientzehuang Pharmaceutical Co Ltd (Pientzehuang), a subsidiary of Zhangzhou Jiulongjiang Construction Co Ltd, is a pharmaceutical company that manufactures and markets traditional Chinese medicines. The company develops medicines and health products, cosmetics, daily chemicals, medical apparatus and instruments, and health food. Its products include pien tze huang capsules, chuangbei qingfei syrup, zengru gao, huoxiang zhengqi shui, xinshubao tablet, qingre zhikegranule, jint...
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.